Although P-McD syndrome only has a small global market - the importance of this application is that it shows 2591 works across a much broader spectrum than trof. It also allows Neuren to apply for orphan drug and fast track other indications.
While it seems not much has happened on the corporate front with trof, seems that 2591 is continuing well should be promising.
Ann: Update on development plan for NNZ-2591, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |